An 81.8% fibrosis response rate in only 11 treated patients sounds almost too clean, which is exactly why the methodology behind that number matters as much as the number itself. D&D Pharmatech’s zabopegdutide posted those figures in a Phase 2 MASH trial, but the more clinically interesting development is what HistoIndex‘s AI pathology tool, qFibrosis, added to the interpretation. Independent of the blinded pathologist read reported last month, the AI analysis of 48-week biopsies showed an average 41.0% relative reduction in continuous qFibrosis score among treated patients against a 9.5% increase in the placebo group (p less than 0.001). That’s not confirmation of a result; it’s a second, fully orthogonal signal pointing in the same direction.
The distinction between categorical staging and continuous quantification is worth unpacking. Standard NASH CRN histological scoring assigns fibrosis in whole-stage increments, a system that can miss meaningful within-stage change and introduces substantial inter-reader variability. qFibrosis measures collagen architecture on a continuous scale from stain-free imaging, which captures gradient shifts that categorical reads simply discard. The fact that both methods converged on the same treatment effect in a cohort this small strengthens the biological credibility of zabopegdutide’s signal. Zabopegdutide is a GLP-1/glucagon dual agonist with an 11:1 GLP-1-to-glucagon potency ratio, designed to drive hepatic benefit beyond the weight-loss pathway alone, and the fibrosis data emerging here suggest the glucagon component may be doing meaningful antifibrotic work rather than just acting as metabolic ballast.
The competitive backdrop has sharpened considerably. Semaglutide received FDA accelerated approval for MASH in August 2025, the first GLP-1 receptor agonist cleared for the indication, and resmetirom (Rezdiffra) was approved in March 2024 for noncirrhotic MASH with F2-to-F3 fibrosis. D&D Pharmatech is therefore not building into a vacuum; differentiation at the Phase 3 design level will require clear positioning on fibrosis stage, cirrhotic versus noncirrhotic populations, and what kind of histological endpoint the FDA will accept. The AI-quantified data reported here could inform exactly that argument, particularly if D&D pushes for a continuous fibrosis metric as a co-primary or surrogate endpoint rather than relying solely on categorical staging.
The single marker to track from here is whether HistoIndex’s qFibrosis data appear in a peer-reviewed publication or a major liver congress abstract before Phase 3 planning is disclosed. Regulators and payers will want to see the methodology stress-tested in a larger, independent cohort before a continuous AI score carries any weight in a registration trial. If that validation moves quickly, it changes the endpoint conversation for the whole MASH field, not just for zabopegdutide.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
